The behavioral pharmacological profile of a drug in a pertinent species is necessary to evaluate quantitatively how the drug functions as a reinforcer or a punisher as well as to establish its stimulus effects. Schedules of food presentation with both fixed-interval and fixed-ratio components have been used most frequently in this type of study since they generate a wide range of rates and patterns of responding within a session and provide stable, long-term baselines for chronic studies in individual animals. The present project involves the assessment of both the acute and chronic effects of a variety of drugs on schedule-controlled behavior. We have recently shown that the enhanced sensitivity observed to the behavioral effects of the opioid antagonist naltrexone is influenced by GABAergic processes, and in particular by an action at the GABA associated chloride channel. Further, this sensitivity may be associated with changes in both mu and delta opioid receptors. Genetic factors are known to influence the behavioral effects of a number of different drugs, and studies of the interactions between environmental and genetic components that potentially affect the development of behavioral tolerance and sensitivity are being initiated. Behaviorally active drugs can also serve as discriminative stimuli to guide behavioral choice. Two- and three-lever drug discrimination projects in the laboratory have helped to define and characterize the spectrum of behavioral effects produced by the drug, to compare a range of other compounds, such as cocaine, l-deprenyl, morphine, midazolam, and caffeine to characterize the relative potency and efficacy to produce drug-like effects, and to evaluate the drug's mechanisms of action at the receptor level. Since most human drug-taking behavior involves chronic long-term use of an illicit drug or non-medical abuse of a prescribed medication, the consequences of chronic administration of drugs on schedule-controlled behavior and the discriminative functions of drugs are being evaluated. Although the development of tolerance and dependence are related to pharmacological factors, tolerance can also be modified by environmental factors. For example, the interaction between drug administration and the ability to perform the task can result in differential tolerance that is a function of chronic daily dose and duration of treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000003-09
Application #
3752828
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1994
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Mazzola, Carmen; Medalie, Julie; Scherma, Maria et al. (2009) Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn Mem 16:332-7
Justinova, Zuzana; Munzar, Patrik; Panlilio, Leigh V et al. (2008) Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. Neuropsychopharmacology 33:2870-7
Le Foll, Bernard; Forget, Benoit; Aubin, Henri-Jean et al. (2008) Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol 13:239-52
Le Foll, Bernard; Justinova, Zuzana; Tanda, Gianlugi et al. (2008) [Future medications for tobacco and cannabis dependence] Bull Acad Natl Med 192:45-56;discussion 56-7
Ferre, Sergi; Ciruela, Francisco; Borycz, Janusz et al. (2008) Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Front Biosci 13:2391-9
Ferre, S; Diamond, I; Goldberg, S R et al. (2007) Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain. Prog Neurobiol 83:332-47
Solinas, Marcello; Yasar, Sevil; Goldberg, Steven R (2007) Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res 56:393-405
Solinas, Marcello; Scherma, Maria; Tanda, Gianluigi et al. (2007) Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. J Pharmacol Exp Ther 321:1127-34
Le Foll, Bernard; Chefer, Svetlana I; Kimes, Alane S et al. (2007) Validation of an extracerebral reference region approach for the quantification of brain nicotinic acetylcholine receptors in squirrel monkeys with PET and 2-18F-fluoro-A-85380. J Nucl Med 48:1492-500
Borycz, Janusz; Pereira, M Fatima; Melani, Alessia et al. (2007) Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments. J Neurochem 101:355-63

Showing the most recent 10 out of 103 publications